Annual Financials for Harrow Health Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
26.77M | 41.37M | 51.17M | 48.87M | 72.48M | |
Sales Growth |
- | 54.52% | 23.67% | -4.48% | 48.30% | |
Cost of Goods Sold (COGS) incl. D&A |
13.51M | 16.52M | 16.75M | 14.46M | 18.21M | |
COGS excluding D&A |
11.74M | 14.68M | 14.09M | 11.72M | 15.82M | |
Depreciation & Amortization Expense |
1.77M | 1.84M | 2.66M | 2.74M | 2.4M | |
Depreciation |
1.4M | 1.61M | 2.45M | 2.58M | 2.24M | |
Amortization of Intangibles |
364,000 | 235,000 | 209,000 | 167,000 | 161,000 | |
COGS Growth |
- | 22.33% | 1.38% | -13.65% | 25.94% | |
Gross Income |
13.27M | 24.85M | 34.42M | 34.41M | 54.26M | |
Gross Income Growth |
- | 87.29% | 38.49% | -0.02% | 57.70% | |
Gross Profit Margin |
- | - | - | - | 74.87% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
25.43M | 30.07M | 34.69M | 34.32M | 52.5M | |
Research & Development |
413,000 | 825,000 | 2.08M | 3.07M | 11.19M | |
Other SG&A |
25.02M | 29.24M | 32.61M | 31.25M | 41.32M | |
SGA Growth |
- | 18.23% | 15.38% | -1.07% | 52.98% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
1.24M | 393,000 | 4.52M | 359,000 | (962,000) | |
EBIT after Unusual Expense |
(1.24M) | (5.61M) | (4.52M) | (270,000) | 2.72M | |
Non Operating Income/Expense |
- | 5.42M | 6.44M | (77,000) | 197,000 | |
Non-Operating Interest Income |
- | - | - | - | - | |
Equity in Affiliates (Pretax) |
3.51M | 17.54M | 738,000 | (1.49M) | (15.46M) | |
Interest Expense |
3.03M | 2.73M | 2.5M | 2.24M | 5.44M | |
Interest Expense Growth |
- | -9.85% | -8.36% | -10.56% | 143.11% | |
Gross Interest Expense |
3.03M | 2.73M | 2.5M | 2.24M | 5.44M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(12.92M) | 14.63M | (117,000) | (4.07M) | (17.98M) | |
Pretax Income Growth |
- | 213.20% | -100.80% | -3,382.05% | -341.21% | |
Pretax Margin |
- | - | - | - | -24.80% | NA |
Income Tax |
(935,000) | - | 8,000 | (655,000) | 32,000 | |
Income Tax - Current Domestic |
- | - | 8,000 | 4,000 | 133,000 | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | 659,000 | 101,000 | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(11.99M) | 14.63M | (125,000) | (3.42M) | (18.01M) | |
Minority Interest Expense |
- | - | (293,000) | (62,000) | - | |
Net Income |
(11.99M) | 14.63M | 168,000 | (3.36M) | (18.01M) | |
Net Income Growth |
- | 222.03% | -98.85% | -2,098.21% | -436.40% | |
Net Margin Growth |
- | - | - | - | -24.85% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(11.99M) | 14.63M | 168,000 | (3.36M) | (18.01M) | |
Preferred Dividends |
- | - | - | - | 472,000 | |
Net Income Available to Common |
(11.99M) | 14.63M | 168,000 | (3.36M) | (18.48M) | |
EPS (Basic) |
(0.60) | 0.67 | 0.01 | (0.13) | (0.69) | |
EPS (Basic) Growth |
- | 211.51% | -99.01% | -2,063.64% | -432.87% | |
Basic Shares Outstanding |
20.03M | 21.92M | 25.32M | 25.9M | 26.76M | |
EPS (Diluted) |
(0.60) | 0.61 | 0.01 | (0.13) | (0.69) | |
EPS (Diluted) Growth |
- | 202.64% | -98.96% | -2,125.00% | -432.87% | |
Diluted Shares Outstanding |
20.03M | 23.81M | 26.47M | 25.9M | 26.76M | |
EBITDA |
(10.4M) | (3.37M) | 2.39M | 2.83M | 4.16M | |
EBITDA Growth |
- | 67.55% | 170.78% | 18.59% | 46.82% | |
EBITDA Margin |
- | - | - | - | 5.74% | NA |